| Entry |
| ||||||
|---|---|---|---|---|---|---|---|
| Name | Pralsetinib (USAN/INN); Gavreto (TN) | ||||||
| Product | GAVRETO (Genentech) | ||||||
| Formula | C27H32FN9O2 | ||||||
| Exact mass | 533.2663 | ||||||
| Mol weight | 533.6005 | ||||||
| Structure |  | ||||||
| Class | Antineoplastic DG01918 Tyrosine kinase inhibitor | ||||||
| Remark |
| ||||||
| Efficacy | Antineoplastic, Tyrosine kinase inhibitor | ||||||
| Disease | Non-small cell lung cancer (RET fusion positive) [DS:H00014] Medullary thyroid cancer (RET mutant) [DS:H01592] Thyroid cancer (RET fusion positive) [DS:H00032] | ||||||
| Comment | Treatment of RET-driven malignacies | ||||||
| Target | RET* [HSA_VAR:5979v1] [HSA:5979] [KO:K05126] | ||||||
| Network |
| ||||||
| Pathway |
| ||||||
| Interaction | |||||||
| Brite | Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS L01 ANTINEOPLASTIC AGENTS L01E PROTEIN KINASE INHIBITORS L01EX Other protein kinase inhibitors L01EX23 Pralsetinib D11712 Pralsetinib (USAN/INN) <US> USP drug classification [BR:br08302] Antineoplastics Molecular Target Inhibitors Pralsetinib D11712 Pralsetinib (USAN/INN) Drug groups [BR:br08330] Antineoplastic DG01918 Tyrosine kinase inhibitor DG03223 Pralsetinib D11712 Pralsetinib Target-based classification of drugs [BR:br08310] Protein kinases Receptor tyrosine kinases (RTK) RET family RET* [HSA_VAR:5979v1] D11712 Pralsetinib (USAN/INN) <US> New drug approvals in the USA [br08319.html] New molecular entities and new therapeutic biological products D11712 New drug approvals in the USA, Europe and Japan [br08328.html] Approval dates by FDA, EMA and PMDA D11712 Pharmacogenomic biomarkers [br08341.html] Somatic variations in targeted cancer therapies D11712 Drug groups [BR:br08330] Antineoplastic DG01918 Tyrosine kinase inhibitor DG03223 Pralsetinib | ||||||
| Other DBs |
| ||||||
| KCF data | ATOM 39 1 C8y C 24.0100 -15.2600 2 N5x N 24.0100 -13.8600 3 C8x C 22.8200 -13.1600 4 C8y C 21.5600 -13.8600 5 C8x C 21.5600 -15.2600 6 C8x C 22.8200 -15.9600 7 N4y N 25.2000 -15.9600 8 C8x C 25.2000 -17.3600 9 C8y C 26.4600 -17.8500 10 C8x C 27.3700 -16.7300 11 N5x N 26.5300 -15.6100 12 X F 26.8800 -19.1800 13 C1c C 20.3700 -13.1600 14 N1b N 19.1800 -13.8600 15 C1a C 20.3700 -11.7600 16 C5a C 17.9900 -13.1600 17 C1z C 16.8000 -13.8600 18 O5a O 17.9900 -11.7600 19 C1x C 15.6100 -13.1600 20 C1x C 14.3500 -13.8600 21 C1y C 14.3500 -15.2600 22 C1x C 15.5400 -15.9600 23 C1x C 16.8000 -15.2600 24 O2a O 16.8000 -12.4600 25 C1a C 15.6100 -11.7600 26 C8y C 13.1600 -15.9600 27 N5x N 11.9700 -15.2600 28 C8y C 10.7100 -15.9600 29 C8x C 10.7100 -17.3600 30 C8y C 11.9000 -18.0600 31 N5x N 13.1600 -17.3600 32 C1a C 11.9000 -19.4600 33 N1b N 9.5200 -15.2600 34 C8y C 8.3300 -15.9600 35 N5x N 7.0000 -15.5400 36 N4x N 6.1600 -16.6600 37 C8y C 7.0000 -17.7800 38 C8x C 8.3300 -17.3600 39 C1a C 6.5800 -19.0400 BOND 43 1 1 2 2 2 2 3 1 3 3 4 2 4 4 5 1 5 5 6 2 6 1 6 1 7 1 7 1 8 7 8 1 9 8 9 2 10 9 10 1 11 10 11 2 12 7 11 1 13 9 12 1 14 4 13 1 15 13 14 1 16 13 15 1 #Up 17 14 16 1 18 16 17 1 19 16 18 2 20 17 19 1 21 19 20 1 22 20 21 1 23 21 22 1 24 22 23 1 25 17 23 1 26 17 24 1 #Down 27 24 25 1 28 21 26 1 #Down 29 26 27 2 30 27 28 1 31 28 29 2 32 29 30 1 33 30 31 2 34 26 31 1 35 30 32 1 36 28 33 1 37 33 34 1 38 34 35 2 39 35 36 1 40 36 37 1 41 37 38 2 42 34 38 1 43 37 39 1 |